Physician profile
Lillian Graf
NPI 1881764454
$7,584.83
in general payments reported to CMS, 2019-2025
35 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $306 · 2021: $742 · 2022: $765 · 2023: $1,572 · 2024: $1,806 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,538 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,537.94 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $876.40 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $850.10 | 2021-2025 | Opzelura |
| Abbvie INC. | $729.25 | 2019-2025 | |
| Janssen Biotech, INC. | $697.91 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $427.74 | 2019-2025 | |
| Galderma Laboratories, L.P. | $415.41 | 2022-2025 | Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $408.36 | 2021-2024 | Winlevi, Ilumya |
| Mayne Pharma Commercial LLC | $377.66 | 2023-2024 | |
| Amgen INC. | $321.50 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $283.36 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $254.16 | 2021-2025 | |
| Genzyme Corporation | $251.97 | 2020-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $222.02 | 2019-2025 | Cabtreo |
| Leo Pharma INC. | $220.05 | 2019-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $152.84 | 2019-2025 | Dupixent |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $131.96 | 2022-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Genentech USA, INC. | $119.56 | 2019-2024 | Erivedge |
| Merz North America, INC. | $98.43 | 2021 | |
| Biofrontera INC. | $97.02 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Dermira, INC. | $71.93 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $68.83 | 2025 | Zoryve |
| Almirall LLC | $66.41 | 2019-2022 | |
| Celgene Corporation | $51.00 | 2019 | |
| Merck Sharp & Dohme LLC | $47.15 | 2019 | |
| Ucb, INC. | $35.86 | 2021-2025 | Bimzelx |
| Allergan, INC. | $34.53 | 2019-2022 | |
| Encore Dermatology INC. | $24.84 | 2019 | |
| Sanofi Pasteur INC. | $23.96 | 2023 | |
| Organon LLC | $22.42 | 2025 | Vtama |
| Taro Pharmaceuticals USA, INC. | $22.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.98 | 2023 | Spevigo |
| Paratek Pharmaceuticals, INC. | $16.92 | 2024 | Nuzyra |
| Strata Skin Sciences, INC. | $11.16 | 2019 | |
| Prugen, INC. Pharmaceuticals | $6.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Graf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.